The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback